TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31860203
Drug: Standard low-calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard low-calorie diet (1730 kcal, protein - 87.4 g, fat - 61.4 g, carbohydrates - 207 g)
Study: 31860203
Drug: Personalized diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized diet (2125 kcal, protein - 100.2 g, fat - 75.9 g, carbohydrates - 260 g) with modification of protein component
Study: 29069507
Drug: Mavrilimumab (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (30, 100 or 150 mg)
Study: 29069507
Drug: Mavrilimumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (150 mg)
Study: 19580457
Drug: Intensive bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive bisphosphonate therapy
Study: 9472182
Drug: Ipratropium plus
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium plus albuterol (initial dose of albuterol 2.5 mg followed by 2 more doses at 20-min intervals, ipratropium 0.5 mg combined with the initial dose of albuterol)
Study: 9472182
Drug: Albuterol alone
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol alone (2.5 mg initial dose followed by 2 more doses at 20-min intervals)
Study: 8585220
Drug: Wobe-Mugos (tablets)
Normalized name: pine needle oil (pinus mugo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobe-Mugos (tablets)
Study: 2504075
Drug: Midazolam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.4 mg/kg) and Innovar (0.04 ml/kg)
Study: 2504075
Drug: Chlorprothixene (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene (2.0 mg/kg)
Study: 1091393
Drug: Pentobarbital 60
Normalized name: pentobarbital 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital 60 mg
Study: 1091393
Drug: Pentobarbital 180
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital 180 mg
Study: 1091393
Drug: Diphenhydramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 150 mg
Study: 1091393
Drug: Methapyrilene 50
Normalized name: methapyrilene
DrugBank: Methapyrilene (DB04819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methapyrilene 50 mg
Study: 6928183
Drug: Pentobarbital 100
Normalized name: pentobarbital 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital 100 mg
Study: 28049480
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy rehabilitation program with coaching based on cognitive behavioral therapy (CBT) principles (OTc)
Study: 28049480
Drug: Sensor monitoring
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sensor monitoring added to the occupational therapy intervention (OTcsm)
Study: 19016463
Drug: Narrow-band blue-light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band blue-light therapy
Study: 19016463
Drug: Red-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red-light therapy (control)
Study: 16510061
Drug: H2RAs or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2RAs or PPIs (maintenance therapy)
Study: 10553391
Drug: Conventional postlicensing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postlicensing treatment program (control)
Study: 6412733
Drug: Alaproclate combined
Normalized name: alaproclate
DrugBank: Alaproclate (DB13233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alaproclate combined with morphine
Study: 6412733
Drug: Morphine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine i.v.
Study: 22000309
Drug: Phenytoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (20 mg/kg)
Study: 30516574
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/d)
Study: 27873545
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges containing Lactobacillus reuteri
Study: 19944452
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel and carboplatin (58% underwent three cycles, 42% had six cycles)
Study: 16082607
Drug: Mini-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mini-dose aprotinin (500.000 KIU [70 mg] in the pump)
Study: 10223359
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with 2 g cefotaxime
Study: 10223359
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with 4g piperacillin plus 0.5g tazobactam
Study: 21997545
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin with colonoscopy screening
Study: 21997545
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin with sigmoidoscopy screening
Study: 21997545
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin with colonoscopy and sigmoidoscopy
Study: 15351765
Drug: Cognitive enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive enhancement therapy
Study: 15351765
Drug: Enriched supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched supportive therapy
Study: 16234012
Drug: 50 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mug IFN-gamma intramuscularly daily for 3 months and on alternate days for the subsequent 6 months
Study: 12399271
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g almonds/d for 4 wk
Study: 10196648
Drug: Oral pseudoephedrine
Normalized name: pseudoephedrine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pseudoephedrine (60 mg capsule)
Study: 2177062
Drug: Lisinopril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10, 20, and 40 mg once-daily)
Study: 2177062
Drug: Captopril (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25, 50, and 100 mg twice-daily)
Study: 389483
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenylhydantoin (DPH) therapy for 2 years
Study: 389483
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DPH therapy)
Study: 30238239
Drug: Early stage
Normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early stage periarticular injection (just prior to arthrotomy)
Study: 30238239
Drug: Late stage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late stage periarticular injection (after implanting the prosthesis)
Study: 21459271
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin for median duration of 28 months
Study: 19632099
Drug: Atorvastatin (n=22)
Normalized name: 22:6(n-3)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (n=22)
Study: 17565514
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine (Group L)
Study: 15581045
Drug: Paclitaxel-gemcitabine-trastuzumab (TGH)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-gemcitabine-trastuzumab (TGH) regimen: paclitaxel 80 mg/m2/week, gemcitabine 1000 mg/m2 every 2 weeks, trastuzumab 4 mg/kg loading dose then 2 mg/kg/week for 12 weeks
Study: 3221746
Drug: Droxicam 20
Normalized name: droxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam 20 mg/day for 20 days
Study: 3221746
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day for 20 days
Study: 29941861
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine spray (TL group)
Study: 29941861
Drug: 1 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/h lidocaine infusion (GL group)
Study: 11564123
Drug: Levetiracetam 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 3,000 mg/day
Study: 15290665
Drug: Gabexate mesylate
Normalized name: mesylate
DrugBank: Gabexate (DB12831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesylate (500 mg; n = 381)
Study: 9313755
Drug: Factor analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor analysis of fasting and 2-h postchallenge insulin levels, fasting triglyceride and HDL cholesterol levels, BMI, and waist-to-hip ratio.
Study: 9313755
Drug: Factor analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor analysis of fasting and 2-h levels of glucose and insulin.
Study: 3316152
Drug: Norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 200 mg bid
Study: 20976768
Drug: Dalfampridine (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine (10mg twice daily)
Study: 16841342
Drug: Clinician‐Administered PTSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician‐Administered PTSD Scale for DSM‐IV (CAPS)
Study: 10332907
Drug: Women's Safety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women's Safety in Recovery group (N=48), met three times weekly for one hour
Study: 10332907
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (N=38)
Study: 30547267
Drug: pH-neutral solutions
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-neutral solutions
Study: 28384480
Drug: L-Tyrosine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Tyrosine administration
Study: 28384480
Drug: Bilateral tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral tDCS over DLPFC with L-Tyrosine
Study: 25738670
Drug: VR-CAP (R-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR-CAP (R-CHOP regimen with bortezomib at a dose of 1.3 mg/m² on days 1, 4, 8, and 11)
Study: 23921656
Drug: Licorice gargle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice gargle (Extractum Liquiritiae Fluidum, 0.5 g in 30 mL water)
Study: 23921656
Drug: Sugar-water gargle
Normalized name: SUGAR/WATER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-water gargle (Sirupus Simplex, 5 g in 30 mL water)
Study: 20673585
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G‐CSF) as an adjunct to de novo AML remission induction therapy
Study: 15148493
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G‐CSF)
Study: 15086539
Drug: Misoprostol (0.4‐0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (0.4‐0.8 mg per day) for 6 weeks
Study: 11473954
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (2 mg oestradiol on days 1‐‐12, 2 mg oestradiol plus 1 mg norethisterone acetate (NETA) on days 13‐‐22, and 1 mg oestradiol on days 23‐‐28, n = 19)
Study: 11473954
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (50 microg/day of oestradiol on days 1‐‐13, and 50 microg oestradiol plus 250 microg/day NETA on days 14‐‐28, n = 19)
Study: 8052367
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of 0.75 microgram calcitriol twice weekly (total weekly dose of 5.25 micrograms)
Study: 8052367
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of 0.75 microgram calcitriol daily (total weekly dose of 5.25 micrograms)
Study: 20688442
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17β-oestradiol/2.5 mg dydrogesterone (E 0.5 mg/D 2.5 mg)
Study: 20688442
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17β-oestradiol/5 mg dydrogesterone (E 1mg/D 5 mg)
Study: 20688442
Drug: E 0.5
Normalized name: iodine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 0.5 mg/D 2.5 mg
Study: 15196155
Drug: Intramuscular penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular penicillin (2 MU x 2 times daily)
Study: 15196155
Drug: Intravenous benzyl
Normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous benzyl penicillin (4 MU x 6 times daily)
Study: 15196155
Drug: Intravenous benzyl
Normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous benzyl penicillin
Study: 15196155
Drug: Intramuscular penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular penicillin
Study: 9405029
Drug: HRT (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate)
Study: 9405029
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium lactate 500 mg/day)
Study: 26177352
Drug: Nonoxynol-9 (N9)
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 (N9) gel
Study: 26177352
Drug: Universal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal placebo gel (UPG)
Study: 23022105
Drug: Vacuum-cast Co-Cr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-cast Co-Cr (CC)
Study: 22229185
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg/d
Study: 17467059
Drug: Nefazodone in
Normalized name: Product containing nefazodone in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone in combination with interpersonal psychotherapy (IPT)
Study: 17467059
Drug: IPT in
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT in combination with placebo
Study: 11719944
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tea extracts with sodium lauryl sulfate (1.2% w/v)
Study: 9207726
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray, 50 micrograms to each nostril, bid for 3 weeks
Study: 9207726
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, bid for 3 weeks
Study: 8432773
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (0.25-0.5 U/kg.week, administered sc daily at bedtime)
Study: 3435129
Drug: Intravenous cefodizime
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefodizime (1 g)
Study: 3435129
Drug: Intramuscular cefodizime
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cefodizime (1 g)
Study: 26890440
Drug: Postpartum antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum antibiotic prophylaxis
Study: 26890440
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment following delivery
Study: 26890440
Drug: Post-CD antibiotics
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-CD antibiotics (meta-analysis)
Study: 26890440
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (meta-analysis)
Study: 25124305
Drug: Δ(9)‐THC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9)‐THC (30 mg)
Study: 25124305
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg) + Δ(9)‐THC (5, 15, 30 mg)
Study: 25124305
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg) + Δ(9)‐THC (5, 15, 30 mg)
Study: 23823799
Drug: Agomelatine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25-50 mg/d)
Study: 12192263
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy
Study: 10642057
Drug: L-carnitine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (100 mg/kg per 24 h per os)
Study: 493093
Drug: acebutolol in
Normalized name: acebutolol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol in combination with a diuretic
Study: 24569618
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg daily for 12 weeks
Study: 25858497
Drug: Masitinib plus
Normalized name: masitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib plus gemcitabine (masitinib 9 mg/kg/day, gemcitabine 1000 mg/m²)
Study: 25858497
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus gemcitabine (placebo, gemcitabine 1000 mg/m²)
Study: 20727239
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium and vitamin D supplementation for low bone density (LBD) women.
Study: 19386548
Drug: Standard-dose PCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose PCI (25 Gy in 10 daily fractions of 2.5 Gy)
Study: 19386548
Drug: Higher-dose PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose PCI (36 Gy delivered using either conventional or accelerated hyperfractionated radiotherapy)
Study: 19386548
Drug: Standard-dose PCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose PCI (25 Gy)
Study: 19386548
Drug: Higher-dose PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose PCI (36 Gy)
Study: 11294370
Drug: GW420867X 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 10 mg
Study: 11294370
Drug: GW420867X 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 50 mg
Study: 11294370
Drug: GW420867X 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 100 mg
Study: 11294370
Drug: GW420867X 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 200 mg
Study: 795190
Drug: 0.2% flumethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% flumethasone ointment
Study: 22251106
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 100 ml.h(‐1) (group R(100))
Study: 22251106
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 200 ml.h(‐1) (group R(200))
Study: 22251106
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 1200 ml.h(‐1) (group R(1200))
Study: 20572767
Drug: ω‐3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 group (SRP + dietary supplementation of fish oil 900 mg EPA + DHA + 81 mg aspirin daily)
Study: 16082528
Drug: Losartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan treatment in patients with LVH
Study: 1826569
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel (Marvelon, group A)
Study: 1826569
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing 30-40 micrograms ethinyloestradiol and 50-125 micrograms levonorgestrel (Triphasil, group B)
Study: 6149538
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 100 mg/day in two divided doses
Study: 30496547
Drug: Dance Movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance Movement Therapy (DMT)
Study: 27858846
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + D group (fractional CO2 laser + luliconazole 1% cream)
Study: 27858846
Drug: L group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L group (fractional CO2 laser alone)
Study: 20847065
Drug: Late remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late remote ischaemic preconditioning (L‐RIPC) consisting of three five-minute cycles of upper limb ischaemia and three five-minute pauses using blood pressure cuff inflation 18 hours prior to the operation.
Study: 20847065
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 mg retard administered at 19:00 hours the day before the operation and at 06:00 hours on the day of the operation.
Study: 20847065
Drug: Late remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late remote ischaemic preconditioning (L‐RIPC).
Study: 12843894
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.2% drops twice the day before and twice on the day of the operation
Study: 1957331
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of 0.6 mg digoxin
Study: 1957331
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of 1.2 mg digoxin
Study: 1957331
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) administration of 0.6 mg digoxin
Study: 1957331
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) administration of 1.2 mg digoxin
Study: 6313028
Drug: Theophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (6 mg/kg) while standing